CLO26-112: Durvalumab Versus Pembrolizumab With Gemcitabine and Cisplatin in First-Line Treatment of Advanced Biliary Tract Cancer: A Real-World Comparative Effectiveness Analysis - PubMed
4 hours ago
- #Immunotherapy
- #Biliary Tract Cancer
- #Real-World Evidence
- This real-world study compares the effectiveness of durvalumab versus pembrolizumab, both combined with gemcitabine and cisplatin, as first-line treatments for advanced biliary tract cancer.
- The analysis, designated CLO26-112, aims to provide comparative data on these immunotherapy regimens in a real-world clinical setting.
- The results are published with the PMID 41911807 and DOI 10.6004/jnccn.2025.7384, indicating publication in a journal such as the JNCCN (Journal of the National Comprehensive Cancer Network).